Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug

11 avril 2025
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
 Site référencé:  The Economic Times

The Economic Times 

Israeli probe into the killings of 15 Palestinian medics in Gaza finds 'professional failures'
20/04/2025
US aid cuts strain response to health crises worldwide : WHO
20/04/2025
China's export controls are curbing critical mineral shipments to the world
20/04/2025
It's not your salary, but your savings that make you a millionaire, says Vijay Kedia
20/04/2025
Reliance Industries to announce Q4 earnings, dividend, and fundraising plan on April 25
20/04/2025
BHEL posts 19% revenue growth to Rs 27,350 cr in FY25, hits record order inflows
20/04/2025